Imagine a world where an injured spinal cord could regenerate, a drug could prevent addiction, and a simple blood test could diagnose depression. Ashiwel S. Undieh, PhD, professor of neuroscience and pharmacology at CUNY School of Medicine and a 2021 XSeed Award winner, is developing technologies that may make all three possible. #wewillcure #innovation
About us
Cure is a vibrant healthcare innovation campus in the heart of New York City with a mission to advance health. Supporting healthcare and life science entrepreneurs, Cure offers digital and in-person content, programming, and learnings on critical health and business topics. The campus at 345 Park Avenue South features laboratory and business facilities, office space and premium event venues, including an education center, conference center, and iconic rooftop terrace. Residents and members collaborate across the spectrum of healthcare and focus on diagnostic, device, drug development and production as well as care delivery and public health. For more information, please visit wewillcure.com.
- Website
-
www.wewillcure.com
External link for Cure.
- Industry
- Health and Human Services
- Company size
- 11-50 employees
- Headquarters
- New York, NY
- Type
- Privately Held
- Founded
- 2020
- Specialties
- Life Science, Incubator, Fellowships, healthcare, scientists, doctors, researchers, digitalhealth, science, health, startup, doctors , ecosystems, business, AI, education, cancer, entreprenuer, health equity, access to care, global health, artificial intelligence, events, and start-ups
Locations
-
Primary
345 Park Ave S
New York, NY 10010, US
Employees at Cure.
-
David Ewing Duncan
Journalist, Author, Researcher, Curator, and Advisor
-
Lauren Ruotolo
Creative Media Partnerships & Executive Producer | Keynote Speaker | Disability Advocate
-
Paul Oestreicher
Strategic Communications; Public and Media Relations; Risk/Issues/Crisis/Reputation Management; Thought Leader; Mentor, and Trusted…
-
Charles Kim
COO & CFO | Healthcare, Sustainability, Food & Beverage
Updates
-
Alex Zhavoronkov, PhD, CEO of Insilico Medicine, leads one of the world's top generative artificial intelligence (AI) drug discovery companies. Read more on why AI-powered robotics are integral to Insilico's workflow. https://lnkd.in/eWRKZ3RV If you're in NYC today and want to hear Zhavoronko speak, register for our #GenAI4Pharma event now: https://lu.ma/ljiwgx8a
Alex Zhavoronkov, PhD, CEO of Insilico Medicine, to Address #GenAI4Pharma Showcase at Cure
wewillcure.com
-
Cure. reposted this
Meet Christine Brideau, a translational scientist at Deerfield Discovery and Development (3DC) who helps advance basic research to the clinic. She’s also a judge for Cure.'s #XSeedAwards, which provide up to $250,000 grants to New York City minority- and women-led life science and healthcare startups working on novel preclinical drug development projects. Read more about how Christine got to where she is today – and the top two reasons why she believes drugs fail in the clinic. https://lnkd.in/e-WQvzme
Spotlight on Christine Brideau, Drug Discovery Scientist and XSeed Award Judge
wewillcure.com
-
Today, we are happy to announce that teams led by Carol Troy, MD, PhD, of Columbia University Irving Medical Center, and Paraskevi (Evi) Giannakakou, PhD, of Weill Cornell Medicine, have each been awarded $250,000 grants as winners of the fourth annual XSeed Award. Troy’s and Giannakakou’s teams will also join the Cure. ecosystem and will receive access to peer learning experiences and office hours with investors, entrepreneurs, and business experts to bolster their networks and raise their visibility. #wewillcure #xseed Learn more: https://lnkd.in/eBZb5NSM.
-
Today at NewYorkBIO Innovation Summit, Cure CEO Seema Kumar sat down Johanna (Rodriguez) Grossman, PhD, Head of Healthcare & Life Sciences, Capital Markets at NYSE for a discussion around the need for financial resources, human capital, and leveraging the biotech ecosystem in New York. #innovation #wewillcure
-
Watch the how the latest in mental health advancements is helping create better health outcomes.
www.linkedin.com
-
We were thrilled to partner with Life Sciences Sherpas last week to host over 160 biopharma executives, investors, bankers, lawyers, and entrepreneurs on Cure's rooftop. This event's goal was to help accelerate life science innovation through increased connectivity within the biotech ecosystem. A huge thank you to our supportive sponsors, Barclays, Citi, Cooley LLP, Oppenheimer & Co. Inc., Truist, and UBS. To learn more about the Life Science Sherpa events, read our interview with Andrew W. Lam, PharmD, Managing Director and Head of Biotech Private Equity at Ally Bridge Group. He helped establish the group and explains how its events facilitate thought-provoking discussions and networking opportunities for individuals from corporate, strategy, and finance. https://lnkd.in/e9TGkMmM #events #wewillcure
-
Congratulations to Dori Thomas-Karyat, PhD, founder and CEO of Synthis Therapeutics, Inc., for being an XSeed finalist for developing a potential first-in-class treatment for idiopathic pulmonary fibrosis — a progressive, debilitating lung disease with limited therapeutic options. #wewillcure
Spotlight on XSeed Award Finalist: Dori Thomas-Karyat, PhD, Founder and CEO of Synthis Therapeutics
wewillcure.com
-
We are thrilled to partner with #GenAI4Pharma & Shwen Gwee on September 12th at Cure to discuss #FutureOfPharma and #GenerativeAI where you’ll hear from leaders in the field and innovative startups that are building GenAI/LLM-based solutions for the biopharma industry, across the lifecycle, including; R&D, Clinical, Medical, Commercialization. Panelists and speakers include: ► Alex Zhavoronkov — CEO, Insilico Medicine ► Jared Saul, MD — Chief Medical Officer, Amazon Web Services (AWS) ► Sooah Cho — Partner, SignalFire ► Milind Kamkolkar — Venture Partner, RA Capital Management and more 👉🏻 Register to attend now (space are limited): https://lu.ma/ljiwgx8a
-
In case you missed it watch Cure CEO Seema Kumar who sat down with Alex Zhavoronkov Ph.D., Chairman and CEO of Insilico Medicine. During this episode of Tuesday Talks, Zhavoronkov discusses how generative #AI is being used to transform and accelerate drug discovery, particularly for diseases related to aging, plus exciting news about its latest deal with Exelixis to develop novel drugs for BRCA-mutant tumors - found in breast, ovarian, pancreatic and prostate cancers. #brca1 #brca #drugdiscovery #aiforgood *Cure is an affiliate of Deerfield Management. Affiliates of Deerfield Management have a financial interest in Insilico Medicine.
www.linkedin.com